The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Lymphatic Filariasis (Elephantiasis)

Mosquito-borne nematode infection causing lymphedema and elephantiasis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Lymphatic Filariasis (Elephantiasis)?

Lymphatic filariasis (LF) is a neglected tropical disease affecting approximately 51 million people across 72 countries with another 859 million at risk. The disease is caused by three filarial nematodes: Wuchereria bancrofti (90% of cases, worldwide tropical distribution), Brugia malayi (Southeast Asia, Indonesia, Philippines, India), and Brugia timori (Lesser Sunda Islands, Indonesia). Transmission occurs through bites of infected mosquitoes (Culex, Anopheles, Aedes, Mansonia species) that inject infective L3 larvae which mature in lymphatic vessels into adult worms.

Adult worms (length 4-10 cm) live in lymphatic vessels for 5-7 years, releasing microfilariae into bloodstream where they show nocturnal periodicity. Pathogenesis involves direct mechanical damage to lymphatic vessels, inflammatory response to dying worms (especially with treatment), Wolbachia endosymbiont-driven inflammation, and progressive lymphatic dysfunction with stasis and recurrent bacterial superinfections (acute dermatolymphangioadenitis, ADLA). Clinical features progress through asymptomatic microfilaremia, acute filarial fever and lymphangitis, recurrent ADLA episodes, and chronic stage with hydrocele (most common manifestation in W. bancrofti males), lymphedema progressing to elephantiasis (severe limb enlargement with skin thickening and verrucous changes), chyluria, breast involvement, and tropical pulmonary eosinophilia (TPE).

Diagnosis includes thick blood smear during nocturnal periodicity for microfilariae, antigen detection (W. bancrofti — ICT card test, FTS), antibody serology (Bm14 ELISA, BmR1), molecular PCR, ultrasound for adult worm visualization (filaria dance sign in scrotal lymphatics), lymphoscintigraphy, and histopathology of biopsy specimens. Treatment includes diethylcarbamazine (DEC) 6 mg/kg single dose plus albendazole 400 mg single dose annually (or DEC alone in some regions), or triple-drug therapy with ivermectin, DEC, and albendazole (IDA) where coendemic onchocerciasis is absent. Doxycycline 100 mg daily for 4-6 weeks targets Wolbachia. Mass drug administration through WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF). Surgical management for hydrocele (hydrocelectomy), lymphedema management with compression, exercise, hygiene, and skin care.

Symptoms

Asymptomatic microfilaremia
Acute filarial fever
Acute lymphangitis with retrograde spread
Lymphadenitis (groin, axilla)
Acute dermatolymphangioadenitis (ADLA) episodes
Hydrocele (most common manifestation in males)
Lymphedema (typically lower limbs)
Elephantiasis (severe chronic limb enlargement)
Skin thickening and verrucous changes
Hyperkeratosis and fissuring
Recurrent bacterial superinfection
Chyluria (milky urine from chylous lymph)
Breast involvement (women)
Genital involvement (lymphedema, vulvar elephantiasis)
Tropical pulmonary eosinophilia (TPE)
Nocturnal cough and wheezing
Eosinophilia
Lymphocele formation
Lymphangiectasia
Functional disability and stigma

Risk Factors

Residence in or extended travel to endemic tropical areas
Repeated mosquito bites (Culex, Anopheles, Aedes, Mansonia)
Outdoor occupations in endemic zones
Lack of mass drug administration program coverage
Inadequate vector control measures
Stagnant water sources for mosquito breeding
Tropical rainforest or coastal areas
Climate change affecting vector distribution
Migration patterns
Limited access to DEC and albendazole treatment
Concurrent loiasis (DEC contraindication)
Concurrent onchocerciasis (DEC severe reaction risk)
Pregnancy (DEC contraindication)
Children under 2 years (treatment limitations)
Severe coexisting medical conditions
Immunosuppression
Poor housing without screens or bed nets
Lack of personal protective measures
Long duration of exposure
Genetic susceptibility factors

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Recurrent fevers in returning traveler from endemic area
  • Lower limb swelling with no other explanation
  • Hydrocele in immigrant or traveler
  • Recurrent inguinal lymphadenitis
  • Cough and wheezing with eosinophilia
  • Skin thickening of lower extremities
  • Concerns about elephantiasis development
  • Considering preventive measures for endemic travel
  • Mass drug administration program eligibility
  • Treatment of confirmed lymphatic filariasis
  • Suspected post-treatment reactions
  • Long-term follow-up of treated patients
  • Loiasis or onchocerciasis screening before DEC
  • Surgical evaluation for hydrocele
  • Lymphedema rehabilitation needs

Treatment Methods

01
Comprehensive evaluation by infectious disease or tropical medicine specialist
02
Detailed travel and exposure history
03
Physical examination focused on lymphatics, genitals, breast, lungs
04
Thick blood smear at nocturnal periodicity (10 PM-2 AM) for microfilariae
05
Antigen detection: W. bancrofti immunochromatographic card test (ICT), filariasis test strip (FTS)
06
Antibody serology: Bm14 ELISA, BmR1 for B. malayi
07
Molecular PCR for species identification
08
Ultrasound for filaria dance sign in scrotal lymphatics (adult worm motility)
09
Lymphoscintigraphy for lymphatic function assessment
10
Histopathology of biopsy specimens (rarely needed)
11
Eosinophil count and IgE for TPE diagnosis
12
Loiasis and onchocerciasis screening in coendemic areas before DEC
13
Diethylcarbamazine (DEC) 6 mg/kg single dose annually
14
Albendazole 400 mg single dose annually combined with DEC
15
Triple-drug therapy: ivermectin 200 μg/kg, DEC 6 mg/kg, albendazole 400 mg (IDA) where appropriate
16
Doxycycline 100 mg daily for 4-6 weeks targeting Wolbachia (sterilizes adult worms)
17
Mass drug administration via WHO GPELF programs
18
Hydrocelectomy for hydrocele management
19
Lymphedema management with compression bandaging, garments
20
Decongestive lymphatic therapy (manual lymphatic drainage)
21
Exercise programs to enhance lymphatic flow
22
Strict skin hygiene to prevent ADLA
23
Antibiotic treatment of bacterial superinfection
24
Antibiotic prophylaxis for recurrent ADLA
25
Antifungal therapy for tinea pedis (entry point for bacteria)
26
Self-care training and patient education
27
Limb elevation
28
Vector control with insecticide-treated bed nets
29
Personal protection (DEET repellents, long sleeves)
30
Multidisciplinary care including infectious disease, urology, surgery, physiotherapy
31
Psychological support for stigma and disability

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.